We transform genetic medicine into success stories

We are a leading, science-driven CDMO for AAV and Lentiviruses.

Our offering

Meet our team

Our core beliefs

Cell and gene therapies experience ~2 times more safety concerns and ~4 times more CMC issues than monoclonal antibody assets. Here’s how DINAMIQS transforms them into success stories.

Optimized molecule design pays off

Genome and capsid optimization will save time, improve clinical success and streamline the regulatory part

Scale up should be easy

Eliminate as many variables as possible when moving from early R&D to cGMP scale

Your analytics strategy will be core

Think early-on what to measure, where to measure, how to measure – and why

No compromise on GMP standards

The focus for GMP needs to be on reliable, high quality, reproduceable results

Choose the right partner, once

Stable teams with strong scientific, technical, and regulatory expertise can take you all the way from DNA to commercial

Tackling challenges in viral vector manufacturing

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS works to overcome these challenges.